Cara Therapeutics, Inc. (NASDAQ:CARA) shares are up more than 37.03% this year and recently increased 0.71% or $0.09 to settle at $12.82. Hemispherx Biopharma, Inc. (NYSE:HEB), on the other hand, is down -53.58% year to date as of 12/06/2017. It currently trades at $0.32 and has returned -0.56% during the past week.
Cara Therapeutics, Inc. (NASDAQ:CARA) and Hemispherx Biopharma, Inc. (NYSE:HEB) are the two most active stocks in the Biotechnology industry based on today’s trading volumes. We will compare the two companies based on the strength of various metrics, including growth, profitability, risk, return, and valuation to determine if one is a better investment than the other.
Growth
The ability to consistently grow earnings at a high compound rate is a defining characteristic of the best companies for long-term investment. Comparatively, HEB is expected to grow at a 25.00% annual rate. All else equal, HEB’s higher growth rate would imply a greater potential for capital appreciation.
Cash Flow
Cash is king when it comes to investing. CARA’s free cash flow (“FCF”) per share for the trailing twelve months was -0.30. Comparatively, HEB’s free cash flow per share was -0.06. On a percent-of-sales basis, CARA’s free cash flow was -10.87% while HEB converted -2.13% of its revenues into cash flow. This means that, for a given level of sales, HEB is able to generate more free cash flow for investors.
Liquidity and Financial Risk
Liquidity and leverage ratios are important because they reveal the financial health of a company. CARA has a current ratio of 14.60 compared to 1.70 for HEB. This means that CARA can more easily cover its most immediate liabilities over the next twelve months. CARA’s debt-to-equity ratio is 0.02 versus a D/E of 0.00 for HEB. CARA is therefore the more solvent of the two companies, and has lower financial risk.
Valuation
CARA trades at a P/B of 4.19, and a P/S of 449.79, compared to a P/B of 0.84, and a P/S of 25.77 for HEB. Given that earnings are what matter most to investors, analysts tend to place a greater weight on the P/E.
Analyst Price Targets and Opinions
A cheap stock isn’t a good investment if the stock is priced accurately. To get a sense of “value” we must compare the current price to some measure of intrinsic value such as a price target. CARA is currently priced at a -49.01% to its one-year price target of 25.14. Comparatively, HEB is -97.22% relative to its price target of 11.52. This suggests that HEB is the better investment over the next year.
Risk and Volatility
To gauge the market risk of a particular stock, investors use beta. Stocks with a beta above 1 are more volatile than the market as a whole. Conversely, a beta below 1 implies below average systematic risk. CARA has a beta of 3.02 and HEB’s beta is -0.88. HEB’s shares are therefore the less volatile of the two stocks.
Insider Activity and Investor Sentiment
Short interest is another tool that analysts use to gauge investor sentiment. It represents the percentage of a stock’s tradable shares that are being shorted. CARA has a short ratio of 9.57 compared to a short interest of 3.56 for HEB. This implies that the market is currently less bearish on the outlook for HEB.
Summary
Hemispherx Biopharma, Inc. (NYSE:HEB) beats Cara Therapeutics, Inc. (NASDAQ:CARA) on a total of 10 of the 14 factors compared between the two stocks. HEB generates a higher return on investment, has higher cash flow per share, has a higher cash conversion rate and has lower financial risk. In terms of valuation, HEB is the cheaper of the two stocks on book value and sales basis, HEB is more undervalued relative to its price target. Finally, HEB has better sentiment signals based on short interest.